In the last trading session, 1.58 million shares of the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) were traded, and its beta was 0.89. Most recently the company’s share price was $8.17, and it changed around -$0.56 or -6.41% from the last close, which brings the market valuation of the company to $871.17M. RCKT currently trades at a discount to its 52-week high of $27.71, offering almost -239.17% off that amount. The share price’s 52-week low was $8.06, which indicates that the current value has risen by an impressive 1.35% since then. We note from Rocket Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.64 million shares, with the 3-month average coming to 1.52 million.
Rocket Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 18 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 1 recommended RCKT as a Hold, whereas 12 deemed it a Buy, and 0 rated it as Underweight. Rocket Pharmaceuticals Inc is expected to report earnings per share of -0.58 for the current quarter.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) trade information
Instantly RCKT has showed a red trend with a performance of -6.41% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.80 on recent trading dayincreased the stock’s daily price by 7.16%. The company’s shares are currently down -35.00% year-to-date, but still down -2.16% over the last five days. On the other hand, Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is -18.71% down in the 30-day period. We can see from the shorts that 11.05 million shares have been sold at a short interest cover period of 8.06 day(s).
The consensus price target as assigned by Wall Street analysts is $35.5, which translates to bulls needing to increase their stock price by 76.99% from its current value. Analyst projections state that RCKT is forecast to be at a low of $32 and a high of $39.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 800k in revenue for the current quarter. 10 analysts expect Rocket Pharmaceuticals Inc to make 1M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -11.60%. Rocket Pharmaceuticals Inc earnings are expected to increase by 14.70% in 2025, but the outlook is positive 73.89% per year for the next five years.
RCKT Dividends
Rocket Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.02% of Rocket Pharmaceuticals Inc shares, and 106.90% of them are in the hands of institutional investors. The stock currently has a share float of 110.22%. Rocket Pharmaceuticals Inc stock is held by 315.0 institutions, with RTW INVESTMENTS, LP being the largest institutional investor. By 2024-06-30, it held 18.8677% of the shares, which is about 17.69 million shares worth $380.82 million.
WELLINGTON MANAGEMENT GROUP LLP, with 9.7665% or 9.16 million shares worth $197.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Health Care Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 6.49 shares worth $53.03 million, making up 6.09% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.62 shares worth around $21.42 million, which represents about 2.46% of the total shares outstanding.
